Use access key #2 to skip to page content.
$25.75 -0.57 (-2.17%)
7/18/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

1

Avatar faroutpicks (< 20) Submitted: 10/18/07 10:18 PM : Outperform Start Price: $45.62 AMLN Score: -25.89

Not sure when the FDA will approve their drug for diabeties, but if it only takes one hit per week my baby boomer bros will be relieved. I don't have type 1 or type 2, but if I sit too long rating stocks and don't exercise I will be headed in that direction.

Report this Post Replies: 0 | Reply

Featured Broker Partners